drugset / Trial / NCT01911065

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

NCT01911065

Non-randomizedParallel-groupOpen-labelPrevention

Summary

In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.

Timeline

Start
2010-09
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Varivax Vaccine 0.65 ml Subcutaneous

Indications